Oved Amitay | CEO

Oved Amitay, CEO, SOLVE M.E.

Oved Amitay is a pharmacologist by training, a drug-developer by trade, and a patient-advocate by choice. He serves as President and Chief Executive Officer at the Solve ME/CFS Initiative- a national organization devoted to making Myalgic Encephalomyelitis (also known as chronic fatigue syndrome or ME/CFS) and other infection-associated diseases such as Long-Covid, understood, diagnosed and treatable. Oved is has dedicated most of his professional career to the development of life-changing therapeutic options for people affected by rare genetic diseases, that resulted in eight Orphan Drugs approved by the FDA. While not rare, infection-associated diseases are also poorly understood, are often missed or misdiagnosed, and suffer from lack of research funding and interest. Oved is using his extensive biotech experience to help bring a change to this space. Oved and his organization were early to recognize the emerging concern that some people with COVID who were infected by SARS-CoV-2 may continue to struggle and develop a post infection condition, that we now call Long COVID. In the summer of 2020 Oved co-authored an op-ed calling for an immediate research effort to be initiated, and later co-founded the Long Covid Alliance, building a network of patient-advocates, scientists and disease experts to collaborate and share their collective knowledge to transform our understanding and treatment of Long COVID and associated diseases. Together, their advocacy led to Congress directing $1.15B to the NIH for funding of Long Covid research. As the pandemic continues, Solve is pushing for more comprehensive solutions to address this mass-disabling disease, and its report on the economic, social and workplace impact of Long Covid was recently featured in the Milken institute’s Review. Throughout his career, Oved has had extensive engagements with healthcare systems and patient advocacy organizations around the world, forging collaborations for patient registries and natural history studies for drug development. One of Solve M.E.’s flagship programs is the You+ME Registry and Biobank, an online clinical study of individuals living with ME/CFS, people with long COVID, and control volunteers. Oved uses his extensive R&D background that to advance research initiatives, and foster public-private partnerships. Oved’s leadership and expertise are recognized by government agencies, researchers and the community, and he is invited often to speak about these topics. Prior to joining Solve M.E., Oved served as Chief Business Officer at CENTOGENE (NASDAQ: CNTG), a global leader in the diagnostics of rare hereditary disorders. He held the position of President and Chief Operating Officer at Arrett Neuroscience, where he led the company’s efforts to develop therapies for Rett syndrome. Prior to that, Oved had senior executive positions at top-tier biotech companies- Alnylam Pharmaceuticals (NASDAQ: ALNY) and Genzyme Corporation (now Sanofi Genzyme).


Day 3 - November 30 @ 13:45

Advancing R&D of long COVID & post-viral diseases through public-private partnerships

last published: 02/Jan/24 12:15 GMT

back to speakers